Filing summary
Entity and period: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 12, 2018. This does not match the request metadata identifying “Solana Co” and “2017 Q4”; verify the intended company and filing. The company reports in U.S. dollars and changed its fiscal year-end to December 31 in 2017.
Business context and reporting period
Helius is a development-stage medical technology company. Its lead candidate, the PoNS device, delivers electrical stimulation through the tongue and is intended to be used with targeted physical or cognitive therapy. The initial target is chronic balance deficit associated with mild-to-moderate traumatic brain injury (TBI). The company had no commercial product revenue and remained dependent on outside capital.
Key financial metrics
| Metric | 2017 | Comparable period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $14.4 million | $4.7 million for the nine months ended December 31, 2016 |
| General and administrative expense | $8.5 million | $5.7 million for the nine months ended December 31, 2016 |
| Operating loss | $22.9 million | $10.4 million for the nine months ended December 31, 2016 |
| Net loss | $28.0 million | $12.0 million for the nine months ended December 31, 2016 |
| Net loss per share, basic and diluted | $1.50 | $0.72 for the nine months ended December 31, 2016 |
| Cash used in operating activities | $19.3 million | $7.9 million for the nine months ended December 31, 2016 |
| Cash provided by financing activities | $22.2 million | $8.0 million for the nine months ended December 31, 2016 |
The audited financial statements compare 2017 with the nine months ended December 31, 2016, not a full prior year. Management also presents unaudited calendar-year 2016 comparisons in its discussion: 2016 revenue was $0; operating expenses were $13.3 million; net loss was $15.9 million; and operating cash use was $9.6 million. Treat these comparisons as different periods and bases. Gross margin and other operating margins are not meaningful because there was no revenue.
At December 31, 2017, cash was $5.6 million, working capital was $1.9 million, total assets were $6.8 million, and current liabilities were $14.3 million. Liabilities included $9.6 million of derivative financial instruments, accounts payable of $3.5 million, and accrued liabilities of $1.2 million. The filing does not identify conventional borrowings as a material balance-sheet item. Accumulated deficit was $66.4 million; stockholders’ deficit was $7.5 million.
Material changes versus prior comparable period
- R&D expense rose substantially as the company conducted its registrational TBI trial and advanced device design, engineering verification, manufacturing preparation, and regulatory work.
- For the audited nine-month comparison, net loss increased from $12.0 million to $28.0 million, and operating cash use increased from $7.9 million to $19.3 million. These periods are not equal in length.
- Derivative remeasurement expense was $3.4 million in 2017, versus $2.5 million for calendar 2016 in management’s unaudited comparison. The 2017 charge was non-cash and reflected changes in valuation inputs and warrant activity.
- Foreign-exchange loss was $1.7 million in 2017 versus a $0.2 million loss for calendar 2016, principally related to Canadian-dollar balances.
- Cash increased from $2.7 million at year-end 2016 to $5.6 million at year-end 2017, supported by $22.2 million of net financing cash flow, including equity and warrant-related proceeds. The company issued shares in public and private offerings during 2017.
Outlook, risks and unusual items
- Funding and going concern: Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern. The filing said year-end cash was insufficient to fund all steps needed for commercialization and that existing resources would not fund operations beyond the first half of 2018 without additional capital. Management expected continued losses.
- Regulatory plans: After completing its registrational TBI trial in the third quarter of 2017, the company planned to submit an FDA de novo application and pursue marketing authorizations in Canada, Europe, and Australia during the first half of 2018. It anticipated U.S. authorization in the second half of 2018, but approval and timing were uncertain.
- Clinical results: In the registrational trial, combined treatment groups showed mean improvements in composite Sensory Organization Test scores of 18.3 points at two weeks and 24.6 points at five weeks; both were reported at p<0.0005. The company reported reduced falls and headaches and no serious device-related adverse events. A separate long-term study reported average improvement of 29.7 points after 14 weeks in the high-frequency group and maintenance of benefit over a 12-week washout. These are company-reported trial results, not evidence of regulatory approval or commercial effectiveness.
- Commercialization and reimbursement: The company had no customer sales contracts, no established reimbursement code or coverage, and no guarantee of U.S. Army purchases. Adoption depends on regulatory authorization, manufacturing readiness, trained therapists, payer coverage, and customer demand.
- Manufacturing and agreements: Key Tronic was selected as contract manufacturer in December 2017. The U.S. Army cost-sharing agreement provided reimbursement up to $3.0 million; the company reported receiving that amount, including $0.2 million recorded as an advance against the final milestone. The CRADA and cost-sharing agreement were extended through 2018, with commercialization obligations extending to 2021. Failure to meet specified conditions could risk rights to the technology and regulatory materials. A separate agreement with A&B included a potential $2.0 million penalty tied to specified milestones; management assessed payment as remote.
- Subsequent financing: On February 28, 2018, A&B exercised 555,556 warrants for approximately $3.8 million gross proceeds. This occurred after the balance-sheet date and is not included in year-end cash.
- Unusual loss and control matter: A business email compromise in 2017 caused a loss of approximately $0.2 million; the company reported no recovery by the filing date. Management disclosed a material weakness in internal control over financial reporting associated with the fraud and said payment-verification controls were enhanced. Management nevertheless concluded disclosure controls and internal control over financial reporting were effective as of year-end.
Most important facts for investors to verify
- Confirm that Helius Medical Technologies, Inc., rather than Solana Co, is the intended issuer and that the desired period is the year ended December 31, 2017.
- Review audited statements and notes for the exact comparative periods, cash runway, derivative-liability valuation, and any financing after year-end.
- Check subsequent regulatory filings for whether FDA and foreign applications were submitted, accepted, or authorized, and whether timelines or clinical conclusions changed.
- Verify the terms and status of the U.S. Army arrangements, the A&B license discussions and potential penalty, and Key Tronic manufacturing readiness.
- Assess future capital needs, potential dilution, reimbursement progress, and any update on recovery of the $0.2 million fraud loss or remediation of the disclosed control weakness.